Entero Therapeutics (ENTO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ENTO Entero Therapeutics

Watchlist

0.412
-0.028-6.38%

Trading Nov 19 10:09 ET

1.96MMarket Cap0.03P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
Yahoo FinanceNov 14 08:00 ET
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business WireNov 13 21:45 ET
Entero Mulls Reverse Merger With Journey Therapeutics
Seeking AlphaNov 13 08:34 ET
Entero Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 13 07:17 ET · Announcements
Express News | Entero Therapeutics Inc - Journey Shareholders to Acquire 99% of Entero Equity
ReutersNov 13 07:00 ET
Express News | Entero Therapeutics Announces Proposed Reverse Merger With Journey Therapeutics, a Clinical Stage, First-in-Class, Next-Generation ADC-Rivalling Nano-Immunoconjugates Biopharmaceutical Company
ReutersNov 13 07:00 ET

Comments

Jaguar8

Nov 13 06:01

NEWS

$Entero Therapeutics (ENTO.US)$
Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
• Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey's next-gen, first-in-class ADC-rivalling, nano-immunoconjugates ("NIC") platform and therapeutic products for unmet medical needs in oncology and autoimmu...